It's a "gateway to embryo editing to do enhancements." The post Scientists Concerned Latest Gene Editing of Human Embryos ...

Emerging gene editing platforms are revolutionizing precision medicine, enabling safe and effective genetic modifications for ...

Intellia Therapeutics, Inc. NTLA stock is trading higher on Monday on additional positive findings from its global Phase 3 ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Researchers relied on a newer gene-editing technique that may make it possible to engineer embryos, a prospect that has long ...

CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time.

COMMENTARY: Why is this latest development generally being hailed as a scientific milestone rather than a giant ethical ...

India, June 14 -- Researchers at Amsterdam UMC, working alongside several partner hospitals, have completed the world's first ...

A team in the US has reported promising results after using an improved form of CRISPR to gene-edit human embryos, but a ...

For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...